Literature DB >> 17203762

Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy.

R Golfieri1, E Giampalma, M Renzulli, A Galuppi, L Vicenzi, M C Galaverni, A Cappelli.   

Abstract

Klatskin-type cholangiocarcinoma is a rare tumor, bearing a very poor prognosis: at diagnosis, most patients can only undergo palliation. Evaluation of outcome, mean survival and quality of life was performed in patients with unresectable hilar cholangiocarcinoma treated with multimodality approach in comparison with surgical palliation, biliary stenting or brachytherapy alone. Twenty-six patients with hilar cholangiocarcinoma were studied: 16 patients were enrolled in the multimodality protocol (bilateral biliary drainage; Iridium-192 brachytherapy; plastic endoprosthesis or metallic stent positioning and external radiotherapy plus systemic chemotherapy), 5 patients underwent surgical palliation and 5 percutaneous decompression alone. Nine patients completed the protocol and 7 were treated with brachytherapy followed by biliary stenting alone. The multimodality approach obtained mean survival (10 months) similar to that for surgery and higher than that of the brachytherapy and metallic stenting groups (6 and 2.75 months, respectively). The average hospital stay (15 days) was lower than that of the surgical group (20 days). A multimodality approach is a suitable alternative to palliative surgery of unresectable hilar cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17203762

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  8 in total

Review 1.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

2.  Surgical treatment of perihilar cholangiocarcinoma: early results of en bloc portal vein resection.

Authors:  Víctor Molina; Jaime Sampson; Joana Ferrer; Alba Díaz; Juan Ramon Ayuso; Santiago Sánchez-Cabús; Josep Fuster; Juan Carlos García-Valdecasas
Journal:  Langenbecks Arch Surg       Date:  2016-12-23       Impact factor: 3.445

Review 3.  Positioning high-dose radiation in multidisciplinary management of unresectable cholangiocarcinomas: review of current evidence.

Authors:  Supriya Chopra; Ashwathy S Mathew; Reena Engineer; Shyam K Shrivastava
Journal:  Indian J Gastroenterol       Date:  2014-08-20

4.  Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma.

Authors:  Tomáš Andrašina; Vlastimil Válek; Jiří Pánek; Zdeněk Kala; Igor Kiss; Stěpán Tuček; Pavel Slampa
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

5.  Comparison of external beam radiation and brachytherapy to external beam radiation alone for unresectable extrahepatic cholangiocarcinoma.

Authors:  Dustin Boothe; Zachary Hopkins; Jonathan Frandsen; Shane Lloyd
Journal:  J Gastrointest Oncol       Date:  2016-08

Review 6.  Hilar cholangiocarcinoma: diagnosis, treatment options, and management.

Authors:  Kevin C Soares; Ihab Kamel; David P Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

7.  Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?

Authors:  Jun-Ke Wang; Hai-Jie Hu; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  Oncotarget       Date:  2017-07-11

8.  Multimodality treatment in unresectable cholangiocarcinoma.

Authors:  Mahdi Aghili; Hazhir Saberi; Mahtab Mojtahed Zadeh; Fatemeh Jafari; Mohammad-Mehdi Mehrabinejad; Habibollah Dashti; Pejman Saberi; Niloofar Ayoobi Yazdi
Journal:  J Contemp Brachytherapy       Date:  2020-04-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.